Newron Pharmaceuticals S.p.A.

LSE:0QOI UK
Market Cap
$355.36 Million
£290.51 Million GBP
Market Cap Rank
#12913 Global
#271 in UK
Share Price
£16.28
Change (1 day)
+0.49%
52-Week Range
£16.20 - £30.70
All Time High
£30.70
About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more

Newron Pharmaceuticals S.p.A. (0QOI) - Total Liabilities

Latest total liabilities as of June 2025: £59.81 Million GBP

Based on the latest financial reports, Newron Pharmaceuticals S.p.A. (0QOI) has total liabilities worth £59.81 Million GBP as of June 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Newron Pharmaceuticals S.p.A. - Total Liabilities Trend (2005–2024)

This chart illustrates how Newron Pharmaceuticals S.p.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Newron Pharmaceuticals S.p.A. Competitors by Total Liabilities

The table below lists competitors of Newron Pharmaceuticals S.p.A. ranked by their total liabilities.

Company Country Total Liabilities
RITES Limited
NSE:RITES
India ₹33.18 Billion
Guangdong Delian Group Co Ltd
SHE:002666
China CN¥1.67 Billion
Shenzhen Fluence Technology PLC
SHE:300647
China CN¥1.67 Billion
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
China CN¥8.82 Billion
Da-Li Development Co Ltd
TW:6177
Taiwan NT$33.80 Billion
Siam Global House Public Company Limited
BK:GLOBAL
Thailand ฿14.40 Billion
Calbee Inc
PINK:CLBEY
USA $111.67 Billion
BK Technologies Inc
NYSE MKT:BKTI
USA $25.91 Million

Liability Composition Analysis (2005–2024)

This chart breaks down Newron Pharmaceuticals S.p.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 37.81 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.97 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Newron Pharmaceuticals S.p.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Newron Pharmaceuticals S.p.A. (2005–2024)

The table below shows the annual total liabilities of Newron Pharmaceuticals S.p.A. from 2005 to 2024.

Year Total Liabilities Change
2024-12-31 £62.45 Million +11.97%
2023-12-31 £55.77 Million +8.88%
2022-12-31 £51.23 Million +8.12%
2021-12-31 £47.38 Million +39.55%
2020-12-31 £33.95 Million +44.54%
2019-12-31 £23.49 Million +354.97%
2018-12-31 £5.16 Million -2.64%
2017-12-31 £5.30 Million -22.52%
2016-12-31 £6.84 Million -5.83%
2015-12-31 £7.27 Million -6.98%
2014-12-31 £7.81 Million -25.79%
2013-12-31 £10.53 Million -38.21%
2012-12-31 £17.04 Million +144.08%
2011-12-31 £6.98 Million +0.58%
2010-12-31 £6.94 Million -44.00%
2009-12-31 £12.39 Million -15.85%
2008-12-31 £14.73 Million +13.58%
2007-12-31 £12.97 Million -29.13%
2006-12-31 £18.30 Million +182.52%
2005-12-31 £6.48 Million --